| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 24 | 2023 | 2430 | 2.150 |
Why?
|
| Drug Hypersensitivity | 4 | 2023 | 96 | 1.740 |
Why?
|
| Fever | 6 | 2020 | 300 | 1.700 |
Why?
|
| Antimicrobial Stewardship | 3 | 2022 | 84 | 1.550 |
Why?
|
| Typhus, Endemic Flea-Borne | 2 | 2020 | 20 | 1.290 |
Why?
|
| Gentamicins | 4 | 2018 | 94 | 1.260 |
Why?
|
| Candidemia | 4 | 2023 | 40 | 1.060 |
Why?
|
| Antifungal Agents | 6 | 2024 | 291 | 1.020 |
Why?
|
| Candidiasis, Invasive | 4 | 2024 | 19 | 1.000 |
Why?
|
| Candida | 3 | 2014 | 75 | 0.900 |
Why?
|
| Exanthema | 3 | 2020 | 71 | 0.890 |
Why?
|
| Metagenomics | 2 | 2022 | 102 | 0.880 |
Why?
|
| Fever of Unknown Origin | 2 | 2016 | 45 | 0.880 |
Why?
|
| Sepsis | 4 | 2023 | 484 | 0.870 |
Why?
|
| Outpatients | 3 | 2023 | 256 | 0.840 |
Why?
|
| Child | 38 | 2024 | 24626 | 0.800 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 283 | 0.790 |
Why?
|
| Blood Culture | 1 | 2022 | 30 | 0.770 |
Why?
|
| Enterobacter | 1 | 2021 | 14 | 0.750 |
Why?
|
| Meningitis | 2 | 2019 | 98 | 0.740 |
Why?
|
| Respiratory Tract Infections | 2 | 2023 | 274 | 0.740 |
Why?
|
| Pediatrics | 4 | 2020 | 1159 | 0.730 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2021 | 54 | 0.730 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 522 | 0.700 |
Why?
|
| Pneumonia | 2 | 2023 | 326 | 0.680 |
Why?
|
| Angiostrongylus cantonensis | 2 | 2018 | 9 | 0.680 |
Why?
|
| Strongylida Infections | 2 | 2018 | 15 | 0.680 |
Why?
|
| Child Health | 2 | 2024 | 56 | 0.670 |
Why?
|
| Bacteremia | 3 | 2021 | 407 | 0.670 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 887 | 0.640 |
Why?
|
| Rickettsia typhi | 1 | 2019 | 12 | 0.640 |
Why?
|
| Headache | 1 | 2019 | 107 | 0.610 |
Why?
|
| Infant | 20 | 2024 | 12606 | 0.600 |
Why?
|
| Ideal Body Weight | 1 | 2018 | 3 | 0.600 |
Why?
|
| Leukemia | 1 | 2021 | 367 | 0.580 |
Why?
|
| Urinary Tract Infections | 3 | 2016 | 300 | 0.550 |
Why?
|
| Humans | 63 | 2024 | 125375 | 0.550 |
Why?
|
| Child, Preschool | 18 | 2024 | 14154 | 0.530 |
Why?
|
| Eye Infections, Viral | 1 | 2016 | 29 | 0.520 |
Why?
|
| Electronic Health Records | 1 | 2022 | 726 | 0.470 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 264 | 0.460 |
Why?
|
| Culturally Competent Care | 1 | 2015 | 46 | 0.460 |
Why?
|
| Adolescent | 20 | 2024 | 19432 | 0.450 |
Why?
|
| Penicillins | 4 | 2023 | 154 | 0.440 |
Why?
|
| Tropical Medicine | 1 | 2015 | 104 | 0.440 |
Why?
|
| Obesity | 2 | 2018 | 2252 | 0.430 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2016 | 293 | 0.430 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 2 | 2003 | 15 | 0.420 |
Why?
|
| Male | 31 | 2024 | 61573 | 0.420 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 221 | 0.400 |
Why?
|
| Neglected Diseases | 1 | 2015 | 151 | 0.390 |
Why?
|
| Amphotericin B | 1 | 2012 | 90 | 0.390 |
Why?
|
| Retrospective Studies | 17 | 2023 | 16370 | 0.380 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 443 | 0.380 |
Why?
|
| Cross Infection | 3 | 2021 | 325 | 0.360 |
Why?
|
| Serum | 1 | 2011 | 46 | 0.350 |
Why?
|
| Simplexvirus | 1 | 2011 | 104 | 0.350 |
Why?
|
| Herpes Simplex | 1 | 2011 | 55 | 0.340 |
Why?
|
| Global Health | 1 | 2015 | 570 | 0.340 |
Why?
|
| Female | 28 | 2024 | 66827 | 0.340 |
Why?
|
| Cohort Studies | 9 | 2024 | 4829 | 0.340 |
Why?
|
| Neutropenia | 1 | 2011 | 199 | 0.330 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 260 | 0.310 |
Why?
|
| Bacterial Infections | 3 | 2023 | 307 | 0.300 |
Why?
|
| Primary Health Care | 3 | 2023 | 775 | 0.280 |
Why?
|
| Inappropriate Prescribing | 2 | 2020 | 41 | 0.280 |
Why?
|
| Brucella melitensis | 1 | 2007 | 8 | 0.270 |
Why?
|
| Brucellosis | 1 | 2007 | 20 | 0.270 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 31 | 0.270 |
Why?
|
| Streptococcus agalactiae | 2 | 2005 | 99 | 0.270 |
Why?
|
| Fetal Diseases | 1 | 2011 | 457 | 0.260 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 1903 | 0.260 |
Why?
|
| Cough | 1 | 2007 | 94 | 0.260 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 456 | 0.250 |
Why?
|
| Internship and Residency | 2 | 2018 | 1183 | 0.250 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 294 | 0.240 |
Why?
|
| Streptococcal Vaccines | 1 | 2004 | 17 | 0.230 |
Why?
|
| Enterobacteriaceae | 2 | 2014 | 35 | 0.220 |
Why?
|
| Enterococcus faecalis | 2 | 2014 | 47 | 0.220 |
Why?
|
| Vaccines, Conjugate | 1 | 2004 | 78 | 0.220 |
Why?
|
| Osteomyelitis | 1 | 2007 | 209 | 0.220 |
Why?
|
| Politics | 1 | 2024 | 59 | 0.220 |
Why?
|
| Risk Factors | 8 | 2023 | 10298 | 0.220 |
Why?
|
| Texas | 4 | 2020 | 3581 | 0.210 |
Why?
|
| Antibodies, Bacterial | 2 | 2005 | 390 | 0.210 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2014 | 164 | 0.200 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2002 | 37 | 0.200 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2003 | 73 | 0.200 |
Why?
|
| Philadelphia | 1 | 2022 | 27 | 0.190 |
Why?
|
| Cephalosporins | 2 | 2020 | 138 | 0.190 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 26 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2023 | 147 | 0.180 |
Why?
|
| Community-Acquired Infections | 1 | 2023 | 241 | 0.180 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 429 | 0.170 |
Why?
|
| Hypersensitivity | 1 | 2023 | 185 | 0.170 |
Why?
|
| Skin Tests | 1 | 2021 | 78 | 0.170 |
Why?
|
| Triazoles | 2 | 2024 | 140 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2002 | 205 | 0.170 |
Why?
|
| Myalgia | 1 | 2020 | 11 | 0.170 |
Why?
|
| Prednisone | 2 | 2016 | 278 | 0.170 |
Why?
|
| Disease Vectors | 1 | 2020 | 24 | 0.170 |
Why?
|
| Mycoses | 1 | 2021 | 118 | 0.170 |
Why?
|
| Curriculum | 2 | 2015 | 728 | 0.170 |
Why?
|
| Feedback | 1 | 2020 | 165 | 0.160 |
Why?
|
| Immunization | 1 | 2021 | 308 | 0.160 |
Why?
|
| Photophobia | 1 | 2019 | 9 | 0.160 |
Why?
|
| Doxycycline | 1 | 2020 | 117 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2022 | 161 | 0.160 |
Why?
|
| Teaching | 2 | 2012 | 188 | 0.160 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 562 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 277 | 0.150 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 108 | 0.140 |
Why?
|
| Teicoplanin | 1 | 2017 | 4 | 0.140 |
Why?
|
| Choice Behavior | 1 | 2018 | 132 | 0.140 |
Why?
|
| Clostridium Infections | 1 | 2020 | 245 | 0.140 |
Why?
|
| Eye Hemorrhage | 1 | 2016 | 3 | 0.130 |
Why?
|
| Ecchymosis | 1 | 2016 | 11 | 0.130 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 12 | 0.130 |
Why?
|
| Education, Medical | 2 | 2012 | 289 | 0.130 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2011 | 345 | 0.130 |
Why?
|
| Infant, Newborn | 9 | 2015 | 8274 | 0.130 |
Why?
|
| Conjunctival Diseases | 1 | 2016 | 33 | 0.130 |
Why?
|
| Methylprednisolone | 1 | 2016 | 93 | 0.130 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2023 | 479 | 0.130 |
Why?
|
| Macrolides | 1 | 2016 | 29 | 0.130 |
Why?
|
| Program Evaluation | 2 | 2015 | 440 | 0.130 |
Why?
|
| Educational Measurement | 1 | 2018 | 323 | 0.120 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 81 | 0.120 |
Why?
|
| Orbital Diseases | 1 | 2016 | 91 | 0.120 |
Why?
|
| Edema | 1 | 2016 | 137 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 97 | 0.120 |
Why?
|
| Eosinophilia | 1 | 2016 | 101 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2021 | 648 | 0.120 |
Why?
|
| HIV Infections | 1 | 2007 | 1896 | 0.120 |
Why?
|
| Rat-Bite Fever | 1 | 2014 | 4 | 0.120 |
Why?
|
| Streptobacillus | 1 | 2014 | 4 | 0.120 |
Why?
|
| Specialization | 1 | 2015 | 75 | 0.120 |
Why?
|
| Drug Resistance, Fungal | 1 | 2014 | 25 | 0.120 |
Why?
|
| Infant, Premature, Diseases | 2 | 2009 | 245 | 0.120 |
Why?
|
| Antiviral Agents | 2 | 2011 | 768 | 0.110 |
Why?
|
| United States | 8 | 2024 | 10913 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 733 | 0.110 |
Why?
|
| Arthralgia | 1 | 2014 | 56 | 0.110 |
Why?
|
| Coagulase | 2 | 2012 | 23 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1692 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 1026 | 0.110 |
Why?
|
| Chemoprevention | 2 | 2011 | 58 | 0.110 |
Why?
|
| Staphylococcus | 2 | 2012 | 69 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3689 | 0.110 |
Why?
|
| Students, Medical | 1 | 2018 | 354 | 0.110 |
Why?
|
| Critical Pathways | 1 | 2013 | 79 | 0.100 |
Why?
|
| Hypokalemia | 1 | 2012 | 42 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 112 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 290 | 0.100 |
Why?
|
| Equipment Contamination | 1 | 2012 | 37 | 0.100 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2012 | 38 | 0.090 |
Why?
|
| Appendicitis | 1 | 2013 | 128 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2018 | 1001 | 0.090 |
Why?
|
| Culture Media | 1 | 2012 | 181 | 0.090 |
Why?
|
| Infant, Low Birth Weight | 1 | 2012 | 167 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2024 | 12287 | 0.090 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2012 | 316 | 0.090 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 130 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 365 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 418 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1017 | 0.080 |
Why?
|
| Young Adult | 2 | 2021 | 9062 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 144 | 0.080 |
Why?
|
| Infant, Premature | 3 | 2011 | 833 | 0.080 |
Why?
|
| Half-Life | 1 | 2010 | 159 | 0.080 |
Why?
|
| Hip Joint | 1 | 2009 | 37 | 0.080 |
Why?
|
| Shoulder Joint | 1 | 2009 | 26 | 0.080 |
Why?
|
| Eye | 1 | 2011 | 228 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2011 | 257 | 0.080 |
Why?
|
| Medical Records | 1 | 2010 | 191 | 0.080 |
Why?
|
| Animals | 3 | 2020 | 34320 | 0.080 |
Why?
|
| Arthritis, Infectious | 1 | 2009 | 59 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2009 | 140 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3313 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 730 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 375 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 485 | 0.070 |
Why?
|
| Adult | 4 | 2021 | 29546 | 0.070 |
Why?
|
| Skin | 1 | 2011 | 521 | 0.070 |
Why?
|
| Clinical Medicine | 1 | 2008 | 21 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2009 | 252 | 0.070 |
Why?
|
| Elbow Joint | 1 | 2007 | 13 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2014 | 6141 | 0.070 |
Why?
|
| Sternum | 1 | 2007 | 53 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2007 | 136 | 0.060 |
Why?
|
| Pneumonia, Bacterial | 1 | 2007 | 77 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2017 | 318 | 0.060 |
Why?
|
| Aging | 2 | 2010 | 1182 | 0.060 |
Why?
|
| Streptococcal Infections | 2 | 2005 | 241 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3605 | 0.060 |
Why?
|
| Diphtheria-Tetanus Vaccine | 1 | 2004 | 3 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 6558 | 0.060 |
Why?
|
| Carrier State | 1 | 2005 | 76 | 0.060 |
Why?
|
| Tetanus Toxoid | 1 | 2004 | 45 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 118 | 0.060 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2004 | 68 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 143 | 0.060 |
Why?
|
| Serotyping | 1 | 2004 | 178 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2004 | 204 | 0.050 |
Why?
|
| Incidence | 1 | 2011 | 3134 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2004 | 173 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 316 | 0.050 |
Why?
|
| Pneumocystis | 1 | 2002 | 11 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2002 | 43 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2003 | 145 | 0.050 |
Why?
|
| Infectious Disease Medicine | 1 | 2022 | 11 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 153 | 0.050 |
Why?
|
| Aspirin | 1 | 2003 | 222 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 211 | 0.050 |
Why?
|
| Time Factors | 1 | 2011 | 6313 | 0.050 |
Why?
|
| Health Promotion | 1 | 2024 | 386 | 0.050 |
Why?
|
| Prevalence | 2 | 2023 | 2467 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 463 | 0.040 |
Why?
|
| Models, Econometric | 2 | 2011 | 9 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1634 | 0.040 |
Why?
|
| Patient Safety | 2 | 2016 | 398 | 0.040 |
Why?
|
| Palivizumab | 2 | 2011 | 47 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 1172 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 645 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 556 | 0.040 |
Why?
|
| Biopsy | 1 | 2003 | 1244 | 0.040 |
Why?
|
| Research | 1 | 2020 | 263 | 0.040 |
Why?
|
| Logistic Models | 1 | 2023 | 1802 | 0.040 |
Why?
|
| Pregnancy | 1 | 2011 | 7226 | 0.040 |
Why?
|
| Hospitals | 1 | 2020 | 399 | 0.040 |
Why?
|
| Neoplasms | 1 | 2011 | 2799 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 3410 | 0.030 |
Why?
|
| Vaccination | 1 | 2021 | 962 | 0.030 |
Why?
|
| Dried Blood Spot Testing | 1 | 2016 | 21 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 509 | 0.030 |
Why?
|
| Logic | 1 | 2015 | 9 | 0.030 |
Why?
|
| Aged | 3 | 2018 | 19722 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2018 | 262 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2057 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2813 | 0.030 |
Why?
|
| Models, Educational | 1 | 2015 | 74 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 617 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 2909 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1633 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 650 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2003 | 3431 | 0.030 |
Why?
|
| Prognosis | 1 | 2003 | 4686 | 0.030 |
Why?
|
| Government Regulation | 1 | 2013 | 41 | 0.030 |
Why?
|
| Teaching Materials | 1 | 2012 | 16 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 44 | 0.030 |
Why?
|
| Appendectomy | 1 | 2013 | 86 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 183 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 93 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 114 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2013 | 171 | 0.020 |
Why?
|
| Infection Control | 1 | 2013 | 156 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 157 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 359 | 0.020 |
Why?
|
| Health Policy | 1 | 2013 | 214 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 190 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 798 | 0.020 |
Why?
|
| Budgets | 1 | 2011 | 17 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 259 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1791 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1394 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 587 | 0.020 |
Why?
|
| Drainage | 1 | 2009 | 260 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 674 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 1310 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 511 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1270 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 645 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 48 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2005 | 212 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2005 | 207 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 153 | 0.010 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2004 | 173 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 601 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 249 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 186 | 0.010 |
Why?
|
| Vancomycin | 1 | 2004 | 217 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 780 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3056 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1427 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 1169 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 26765 | 0.010 |
Why?
|